trial

Telmisartan Pilot Study on Treatment Resistant Schizophrenia

NCTId NCT03868839
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 6 (actual)
Sponsored by Xiaoduo Fan
Primary completion 2020-10-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
6 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2019-02-01
Primary completion
2020-10-07
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Telmisartan Pill

Sponsors

Xiaoduo FanLead Sponsor

Investigators

1
Xiaoduo Fan, MD, MPH, MSPrincipal Investigator

Sites

1 total
Worcester, United States

Linked catalysts

1
Telmisartan Pilot Study on Treatment Resistant Schizophrenia — primary completion2020-10-07

Facts & assertions

4 sourced
Enrollment
6
Phase
PHASE2
Primary Completion Date
2020-10-07
Status
TERMINATED
relationships
The graph out of here
drug
Telmisartan Pill
drug
lead_sponsor
Xiaoduo Fan
company
indication
Schizo Affective Disorder
indication
Treatment-resistant Schizophrenia
indication
Psychotic Disorders
indication
investigator
Xiaoduo Fan, MD, MPH, MS
person